Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000469479 | SCV000552957 | uncertain significance | Hereditary spastic paraplegia 7 | 2016-08-25 | criteria provided, single submitter | clinical testing | This sequence change replaces serine with asparagine at codon 62 of the SPG7 protein (p.Ser62Asn). The serine residue is weakly conserved and there is a small physicochemical difference between serine and asparagine. This variant is present in population databases at a very low frequency  (rs143294686, ExAC <0.01%) but has not been reported in the literature in individuals with a SPG7-related disease. Algorithms developed to predict the effect of missense changes on protein structure and function output the following: (SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0"). The asparagine amino acid residue is also found in multiple mammalian species, suggesting that this missense change does not adversely affect protein function. These predictions have not been confirmed by published functional studies. In summary, this variant is a rare missense change that is not predicted to affect protein function. There is no indication that it causes disease, but the available evidence is currently insufficient to prove that conclusively. Therefore, it has been classified as a Variant of Uncertain Significance. |
Eurofins Ntd Llc |
RCV000591290 | SCV000703934 | uncertain significance | not provided | 2017-01-04 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV000591290 | SCV002541376 | uncertain significance | not provided | 2021-08-19 | criteria provided, single submitter | clinical testing |